A critical brainstem relay for mediation of diffuse noxious inhibitory controls.

descending pain modulatory system (DPMS) diffuse noxious inhibitory controls (DNIC) in vivo electrophysiology noradrenaline optogenetics pain inhibition wide dynamic range neurons

Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
01 06 2023
Historique:
received: 08 08 2022
revised: 06 11 2022
accepted: 05 12 2022
medline: 2 6 2023
pubmed: 11 1 2023
entrez: 10 1 2023
Statut: ppublish

Résumé

The CNS houses naturally occurring pathways that project from the brain to modulate spinal neuronal activity. The noradrenergic locus coeruleus (the A6 nucleus) originates such a descending control whose influence on pain modulation encompasses an interaction with a spinally projecting non-cerulean noradrenergic cell group. Hypothesizing the origin of an endogenous pain inhibitory pathway, our aim was to identify this cell group. A5 and A7 noradrenergic nuclei also spinally project. We probed their activity using an array of optogenetic manipulation techniques during in vivo electrophysiological experimentation. Interestingly, noxious stimulus evoked spinal neuronal firing was decreased upon opto-activation of A5 neurons (two-way ANOVA with Tukey post hoc, P < 0.0001). Hypothesizing that this may reflect activity in the noradrenergic diffuse noxious inhibitory control circuit, itself activated upon application of a conditioning stimulus, we opto-inhibited A5 neurons with concurrent conditioning stimulus application. Surprisingly, no spinal neuronal inhibition was observed; activity in the diffuse noxious inhibitory control circuit was abolished (two-way ANOVA, P < 0.0001). We propose that the A5 nucleus is a critical relay nucleus for mediation of diffuse noxious inhibitory controls. Given the plasticity of diffuse noxious inhibitory controls in disease, and its back and forward clinical translation, our data reveal a potential therapeutic target.

Identifiants

pubmed: 36625030
pii: 6980486
doi: 10.1093/brain/awad002
pmc: PMC10232242
doi:

Substances chimiques

Norepinephrine X4W3ENH1CV

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2259-2267

Subventions

Organisme : Medical Research Council
ID : MR/W004739/1
Pays : United Kingdom
Organisme : National Centre for the Replacement, Refinement and Reduction of Animals in Research
ID : NC/T002115/1
Pays : United Kingdom

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.

Références

Neuroscience. 2009 Apr 21;160(1):174-85
pubmed: 19223010
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
J Neurosci. 2014 Mar 19;34(12):4148-60
pubmed: 24647936
Pain. 1983 Jun;16(2):109-110
pubmed: 6877845
Elife. 2017 Oct 13;6:
pubmed: 29027903
J Comp Neurol. 2012 Jun 15;520(9):1985-2001
pubmed: 22173709
Sci Adv. 2020 Apr 08;6(15):eaaz4232
pubmed: 32285002
Hum Gene Ther. 2001 Sep 20;12(14):1731-40
pubmed: 11560767
Nat Commun. 2018 Oct 8;9(1):4125
pubmed: 30297821
Brain Res. 2016 Jun 15;1641(Pt B):274-90
pubmed: 26903420
Brain Res. 1992 Jan 31;571(1):140-4
pubmed: 1611486
Eur J Pharmacol. 2006 Dec 3;551(1-3):41-9
pubmed: 17027962
Nat Protoc. 2015 Nov;10(11):1860-1896
pubmed: 26492141
Brain Res. 1993 Jul 9;616(1-2):200-10
pubmed: 7689410
Brain Res. 1991 Jan 11;538(2):231-45
pubmed: 2012966
CNS Drug Rev. 2005 Autumn;11(3):273-88
pubmed: 16389294
Brain. 2022 Jul 29;145(7):2293-2300
pubmed: 35245374
Brain Res. 1983 Mar 14;263(1):15-31
pubmed: 6839168
Nat Neurosci. 2016 Apr;19(4):554-6
pubmed: 26950004
Neuron. 2018 Dec 19;100(6):1491-1503.e3
pubmed: 30449655
Int J Mol Sci. 2020 Apr 23;21(8):
pubmed: 32340137
Neuron. 2016 Oct 19;92(2):372-382
pubmed: 27720486
Eur J Neurosci. 1997 Nov;9(11):2452-61
pubmed: 9464939
Brain Res. 1992 Nov 13;595(2):353-7
pubmed: 1467976
Nat Neurosci. 2020 Nov;23(11):1376-1387
pubmed: 33020652
Brain Res. 1991 May 3;547(2):279-88
pubmed: 1884202
J Neurophysiol. 1990 Dec;64(6):1712-23
pubmed: 2074459
Eur J Pain. 2017 Apr;21(4):750-760
pubmed: 27891703
Pain. 2015 Sep;156(9):1803-1811
pubmed: 26010460

Auteurs

Mateusz W Kucharczyk (MW)

Central Modulation of Pain, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE1 1UL, UK.
Laboratory of Neurophysiology, Department of Biochemical Toxicology, Chair of Toxicology, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow 30-688, Poland.

Francesca Di Domenico (F)

Central Modulation of Pain, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE1 1UL, UK.

Kirsty Bannister (K)

Central Modulation of Pain, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE1 1UL, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH